Pregabalin enhances nonrapid eye movement sleep

Takeshi Kubota, Jidong Fang, Leonard T. Meltzer, James M. Krueger

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Pregabalin, an analog of γ,-aminobutyric acid (GABA) that does not interact with GABA receptors, is in development as an analgesic, an anticonvulsant, and an anxiolytic. We evaluated the potential somnogenic actions of pregabalin in rats and compared it to those of triazolam, a widely used hypnotic. Pregabalin increased the duration of nonrapid eye movement sleep (NREMS) and decreased rapid eye movement sleep (REMS) after either dark onset or light onset administration. Triazolam increased duration of NREMS and had no effect on duration of REMS. Pregabalin markedly increased the duration of NREMS episodes and decreased the number of NREMS episodes. Power spectrum analysis revealed pregabalin-induced dose-dependent increases in relative delta power after administration. In contrast, triazolam decreased electroencephalographic power density in low frequency bands. Results suggest that pregabalin is a potential sleep modulating agent.

Original languageEnglish (US)
Pages (from-to)1095-1105
Number of pages11
JournalJournal of Pharmacology and Experimental Therapeutics
Volume299
Issue number3
StatePublished - 2001

Fingerprint

Eye Movements
Sleep
Triazolam
REM Sleep
Aminobutyrates
GABA Receptors
Anti-Anxiety Agents
Pregabalin
Hypnotics and Sedatives
Anticonvulsants
gamma-Aminobutyric Acid
Action Potentials
Analgesics
Spectrum Analysis
Light

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Kubota, T., Fang, J., Meltzer, L. T., & Krueger, J. M. (2001). Pregabalin enhances nonrapid eye movement sleep. Journal of Pharmacology and Experimental Therapeutics, 299(3), 1095-1105.
Kubota, Takeshi ; Fang, Jidong ; Meltzer, Leonard T. ; Krueger, James M. / Pregabalin enhances nonrapid eye movement sleep. In: Journal of Pharmacology and Experimental Therapeutics. 2001 ; Vol. 299, No. 3. pp. 1095-1105.
@article{6629464763224fdf9d9f381f28995414,
title = "Pregabalin enhances nonrapid eye movement sleep",
abstract = "Pregabalin, an analog of γ,-aminobutyric acid (GABA) that does not interact with GABA receptors, is in development as an analgesic, an anticonvulsant, and an anxiolytic. We evaluated the potential somnogenic actions of pregabalin in rats and compared it to those of triazolam, a widely used hypnotic. Pregabalin increased the duration of nonrapid eye movement sleep (NREMS) and decreased rapid eye movement sleep (REMS) after either dark onset or light onset administration. Triazolam increased duration of NREMS and had no effect on duration of REMS. Pregabalin markedly increased the duration of NREMS episodes and decreased the number of NREMS episodes. Power spectrum analysis revealed pregabalin-induced dose-dependent increases in relative delta power after administration. In contrast, triazolam decreased electroencephalographic power density in low frequency bands. Results suggest that pregabalin is a potential sleep modulating agent.",
author = "Takeshi Kubota and Jidong Fang and Meltzer, {Leonard T.} and Krueger, {James M.}",
year = "2001",
language = "English (US)",
volume = "299",
pages = "1095--1105",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

Kubota, T, Fang, J, Meltzer, LT & Krueger, JM 2001, 'Pregabalin enhances nonrapid eye movement sleep', Journal of Pharmacology and Experimental Therapeutics, vol. 299, no. 3, pp. 1095-1105.

Pregabalin enhances nonrapid eye movement sleep. / Kubota, Takeshi; Fang, Jidong; Meltzer, Leonard T.; Krueger, James M.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 299, No. 3, 2001, p. 1095-1105.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pregabalin enhances nonrapid eye movement sleep

AU - Kubota, Takeshi

AU - Fang, Jidong

AU - Meltzer, Leonard T.

AU - Krueger, James M.

PY - 2001

Y1 - 2001

N2 - Pregabalin, an analog of γ,-aminobutyric acid (GABA) that does not interact with GABA receptors, is in development as an analgesic, an anticonvulsant, and an anxiolytic. We evaluated the potential somnogenic actions of pregabalin in rats and compared it to those of triazolam, a widely used hypnotic. Pregabalin increased the duration of nonrapid eye movement sleep (NREMS) and decreased rapid eye movement sleep (REMS) after either dark onset or light onset administration. Triazolam increased duration of NREMS and had no effect on duration of REMS. Pregabalin markedly increased the duration of NREMS episodes and decreased the number of NREMS episodes. Power spectrum analysis revealed pregabalin-induced dose-dependent increases in relative delta power after administration. In contrast, triazolam decreased electroencephalographic power density in low frequency bands. Results suggest that pregabalin is a potential sleep modulating agent.

AB - Pregabalin, an analog of γ,-aminobutyric acid (GABA) that does not interact with GABA receptors, is in development as an analgesic, an anticonvulsant, and an anxiolytic. We evaluated the potential somnogenic actions of pregabalin in rats and compared it to those of triazolam, a widely used hypnotic. Pregabalin increased the duration of nonrapid eye movement sleep (NREMS) and decreased rapid eye movement sleep (REMS) after either dark onset or light onset administration. Triazolam increased duration of NREMS and had no effect on duration of REMS. Pregabalin markedly increased the duration of NREMS episodes and decreased the number of NREMS episodes. Power spectrum analysis revealed pregabalin-induced dose-dependent increases in relative delta power after administration. In contrast, triazolam decreased electroencephalographic power density in low frequency bands. Results suggest that pregabalin is a potential sleep modulating agent.

UR - http://www.scopus.com/inward/record.url?scp=0035200319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035200319&partnerID=8YFLogxK

M3 - Article

C2 - 11714899

AN - SCOPUS:0035200319

VL - 299

SP - 1095

EP - 1105

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -